Reviews past treatment records of lung cancer patients in China
Looks at treatments and outcomes in people with early to mid-stage non-small cell lung cancer.
Plain-language title generated from the registry record
Registry title: A Multi-centre Chart Review Study of Stage I-III Non-Small Cell Lung Cancer in China
Key facts
- Where
- Beijing, ChinaSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The study looks at medical records of adults in China who were first diagnosed with stage I-III non-small cell lung cancer in set time periods.
- Age
- 18 years or older at first diagnosis of NSCLC
- Sex
- All
- Disease stage
- Stage I-III non-small cell lung cancer (NSCLC) at first diagnosis
Main reasons for not taking part
- NSCLC is not the primary cancer diagnosis
- Recent history of another tumor, or another tumor at the same time
- Taking part in an interventional clinical trial at the time of first diagnosis
- Positive pregnancy status at the time of diagnosis
Read by machine on 9 November 2026.
Where in China
- BeijingHospital not named in the registryTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- AstraZeneca
- Trial code
- NCT07316062
- Record updated
- 21 October 2026
- Original description
This chart review study is proposed in China to understand the treatment patterns, biomarker testing, and clinical outcomes with SOC and some selected regimens among patients diagnosed with stage I-III NSCLC.Read full original descriptionShow less
A Multi-centre Chart Review Study on the Treatment Patterns and Outcomes of Stage I-III Non-Small Cell Lung Cancer in China
This chart review study is proposed in China to understand the treatment patterns, biomarker testing, and clinical outcomes with SOC and some selected regimens among patients diagnosed with stage I-III NSCLC.
Inclusion: Stage I-III at initial NSCLC diagnosis; Aged ≥18 years at first diagnosis of NSCLC; Timeframe of NSCLC diagnosis:; For DE1: diagnosed with NSCLC during the period between May 1st 2025 and December 31st 2025 For DE2: diagnosed with NSCLC during the period between May 1st 2026 and December 31st 2026 For DE3: diagnosed with NSCLC during the period between May 1st 2027 and December 31st 2027.
Exclusion: Patients with a recent history of other tumor or concurrent other tumor; NSCLC is not the primary cancer diagnosis; Patients participating in interventional clinical trials at time of initial diagnosis; Patients with positive pregnancy status at the time of diagnosis.